ADVL 1515: A Phase 1 Study of LY2606368, A CHK 1/2 Inhibitor, in Pediatric Patients with Recurrent or Refractory Solid Tumors, Including CNS Tumors

Grant

Date/time Interval

  • June 28, 2017 - June 27, 2020

    • Awarded By

    Total Award Amount

  • 6500.00

    • Direct Costs

  • 5000.00

    • Sponsor Award Id

    • Contributor

  • Ana Galtarossa Xavier   Investigator  
  • Elizabeth Alva   Investigator  
  • Emily Johnston   Investigator  
  • Gregory Friedman M.D.   Principal Investigator  
  • Jamie Aye   Investigator  
  • Kimberly Whelan M.D.   Investigator  
  • Laura Metrock   Investigator  
  • Matthew Kutny M.D.   Investigator  
  • Wayne Liang   Investigator